300 related articles for article (PubMed ID: 31411929)
1. The Role of Kinase Signaling in Resistance to Bevacizumab Therapy for Glioblastoma Multiforme.
Ramezani S; Vousooghi N; Joghataei MT; Chabok SY
Cancer Biother Radiopharm; 2019 Aug; 34(6):345-354. PubMed ID: 31411929
[TBL] [Abstract][Full Text] [Related]
2. Hypoxia upregulates HIG2 expression and contributes to bevacizumab resistance in glioblastoma.
Mao XG; Wang C; Liu DY; Zhang X; Wang L; Yan M; Zhang W; Zhu J; Li ZC; Mi C; Tian JY; Hou GD; Miao SY; Song ZX; Li JC; Xue XY
Oncotarget; 2016 Jul; 7(30):47808-47820. PubMed ID: 27329597
[TBL] [Abstract][Full Text] [Related]
3. Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.
Navone SE; Guarnaccia L; Cordiglieri C; Crisà FM; Caroli M; Locatelli M; Schisano L; Rampini P; Miozzo M; La Verde N; Riboni L; Campanella R; Marfia G
World Neurosurg; 2018 Dec; 120():e380-e391. PubMed ID: 30144594
[TBL] [Abstract][Full Text] [Related]
4. Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma.
Scholz A; Harter PN; Cremer S; Yalcin BH; Gurnik S; Yamaji M; Di Tacchio M; Sommer K; Baumgarten P; Bähr O; Steinbach JP; Trojan J; Glas M; Herrlinger U; Krex D; Meinhardt M; Weyerbrock A; Timmer M; Goldbrunner R; Deckert M; Braun C; Schittenhelm J; Frueh JT; Ullrich E; Mittelbronn M; Plate KH; Reiss Y
EMBO Mol Med; 2016 Jan; 8(1):39-57. PubMed ID: 26666269
[TBL] [Abstract][Full Text] [Related]
5. Glioblastoma endothelium drives bevacizumab-induced infiltrative growth via modulation of PLXDC1.
Falchetti ML; D'Alessandris QG; Pacioni S; Buccarelli M; Morgante L; Giannetti S; Lulli V; Martini M; Larocca LM; Vakana E; Stancato L; Ricci-Vitiani L; Pallini R
Int J Cancer; 2019 Mar; 144(6):1331-1344. PubMed ID: 30414187
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
7. Assessment of bevacizumab resistance increased by expression of BCAT1 in IDH1 wild-type glioblastoma: application of DSC perfusion MR imaging.
Cho HR; Hong B; Kim H; Park CK; Park SH; Park S; Choi SH
Oncotarget; 2016 Oct; 7(43):69606-69615. PubMed ID: 27626306
[TBL] [Abstract][Full Text] [Related]
8. Rechallenging Recurrent Glioblastoma with Intra-Arterial Bevacizumab with Blood Brain-Barrier Disruption Results in Radiographic Response.
Faltings L; Kulason KO; Patel NV; Wong T; Fralin S; Li M; Schneider JR; Filippi CG; Langer DJ; Ortiz R; Boockvar JA
World Neurosurg; 2019 Nov; 131():234-241. PubMed ID: 31351210
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
Lassen U; Sorensen M; Gaziel TB; Hasselbalch B; Poulsen HS
Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811
[TBL] [Abstract][Full Text] [Related]
10. Shedding of bevacizumab in tumour cells-derived extracellular vesicles as a new therapeutic escape mechanism in glioblastoma.
Simon T; Pinioti S; Schellenberger P; Rajeeve V; Wendler F; Cutillas PR; King A; Stebbing J; Giamas G
Mol Cancer; 2018 Aug; 17(1):132. PubMed ID: 30165850
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of bevacizumab in glioblastomas.
De Fazio S; Russo E; Ammendola M; Donato Di Paola E; De Sarro G
Curr Med Chem; 2012; 19(7):972-81. PubMed ID: 22214463
[TBL] [Abstract][Full Text] [Related]
12. Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine.
Heiland DH; Masalha W; Franco P; Machein MR; Weyerbrock A
J Neurooncol; 2016 Feb; 126(3):567-75. PubMed ID: 26614518
[TBL] [Abstract][Full Text] [Related]
13. Talin1 targeting potentiates anti-angiogenic therapy by attenuating invasion and stem-like features of glioblastoma multiforme.
Kang W; Kim SH; Cho HJ; Jin J; Lee J; Joo KM; Nam DH
Oncotarget; 2015 Sep; 6(29):27239-51. PubMed ID: 26336988
[TBL] [Abstract][Full Text] [Related]
14. Neuropilin-1 modulates TGFβ signaling to drive glioblastoma growth and recurrence after anti-angiogenic therapy.
Kwiatkowski SC; Guerrero PA; Hirota S; Chen Z; Morales JE; Aghi M; McCarty JH
PLoS One; 2017; 12(9):e0185065. PubMed ID: 28938007
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia suppresses cylindromatosis (CYLD) expression to promote inflammation in glioblastoma: possible link to acquired resistance to anti-VEGF therapy.
Guo J; Shinriki S; Su Y; Nakamura T; Hayashi M; Tsuda Y; Murakami Y; Tasaki M; Hide T; Takezaki T; Kuratsu J; Yamashita S; Ueda M; Li JD; Ando Y; Jono H
Oncotarget; 2014 Aug; 5(15):6353-64. PubMed ID: 25071012
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Combination Therapy with MET and VEGF Inhibitors for MET-overexpressing Glioblastoma.
Okuda T; Tasaki T; Nakata S; Yamashita K; Yoshioka H; Izumoto S; Kato A; Fujita M
Anticancer Res; 2017 Jul; 37(7):3871-3876. PubMed ID: 28668888
[TBL] [Abstract][Full Text] [Related]
17. Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.
Piao Y; Park SY; Henry V; Smith BD; Tiao N; Flynn DL; de Groot JF
Neuro Oncol; 2016 Sep; 18(9):1230-41. PubMed ID: 26965451
[TBL] [Abstract][Full Text] [Related]
18. Soluble CD146, a biomarker and a target for preventing resistance to anti-angiogenic therapy in glioblastoma.
Joshkon A; Tabouret E; Traboulsi W; Bachelier R; Simoncini S; Roffino S; Jiguet-Jiglaire C; Badran B; Guillet B; Foucault-Bertaud A; Leroyer AS; Dignat-George F; Chinot O; Fayyad-Kazan H; Bardin N; Blot-Chabaud M
Acta Neuropathol Commun; 2022 Oct; 10(1):151. PubMed ID: 36274147
[TBL] [Abstract][Full Text] [Related]
19. Chloroquine inhibits the malignant phenotype of glioblastoma partially by suppressing TGF-beta.
Roy LO; Poirier MB; Fortin D
Invest New Drugs; 2015 Oct; 33(5):1020-31. PubMed ID: 26271735
[TBL] [Abstract][Full Text] [Related]
20. Single-agent Bevacizumab in Recurrent Glioblastoma After Second-line Chemotherapy With Fotemustine: The Experience of the Italian Association of Neuro-Oncology.
Pasqualetti F; Pace A; Gonnelli A; Villani V; Cantarella M; Delishaj D; Vivaldi C; Molinari A; Montrone S; Pellerino A; Franchino F; Baldaccini D; Lombardi G; Lolli I; Catania F; Bazzoli E; Morganti R; Fabi A; Zagonel V; Bocci G; Fabrini MG; Rudà R; Soffietti R; Paiar F
Am J Clin Oncol; 2018 Dec; 41(12):1272-1275. PubMed ID: 29782366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
